ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2721

Venous Thromboembolism in ANCA Associated Vasculitis. a Population-Based Cohort Study from Southern Sweden

Matina Liapi1, David Jayne2, Mårten Segelmark3 and Aladdin Mohammad4, 1Medicine, Blekinge Hospital, Karlskrona, Sweden, 2Department of Medicine, University of Cambridge, Cambridge, United Kingdom, 3Clinical Sciences, Nephrology, Lund University, Lund, Sweden, 4Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: ANCA, Disease Activity, outcomes, thrombosis and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Vasculitis – ANCA-Associated Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

To estimate the rate and predictors of venous thromboembolic events (VTEs) in a population-based cohort of patients with ANCA- associated vasculitis (AAV).

Methods:

322 patients (47% women) diagnosed with AAV between 1997 and 2016 from a well-defined population in southern Sweden, were included in this study. The diagnosis of AAV and VTEs were ascertained by review of medical records. Radiological investigations, clinical notes, laboratory results and prescriptions of anticoagulation therapies were reviewed to identify patients with VTEs. Demographics, clinical and laboratory data were collected from time of AAV diagnosis until death or end of follow-up, September 2017. Birmingham Vasculitis Activity Score (BVAS) was used to assess AAV disease activity. Organ damage was assessed by vasculitis damage index (VDI). VTEs occurred within 3 months prior to AAV diagnosis and any time after that were considered as AAV-related VTEs.

Results:

55 patients (17%) developed a total of 63 VTEs of which 31 cases were deep vein thrombosis, 21 pulmonary embolisms and 11 other VTEs (5 retinal vein thrombosis, 1 sinus thrombosis, 1 subclavian vein thrombosis, 2 cases of jugular vein thrombosis, 1 right ventricle thrombosis, 1 olecranon bursa vein thrombosis). Of all patients with VTEs, 45 (82%) developed AAV-related VTE resulting in an incidence rate of 2.4/100 person-years (95% CI 1.7-3.1) during 1906 person-year of follow-up. The incidence rate of AAV-related VTEs during first year from diagnosis of AAV was estimated to 10.9/100 person-year (95% CI 6.8-14.9), decreased to 6.2 at 2-years (p=0.07), 3.9 at 5-years (p<0.001) and 2.8 at 10 years from diagnosis of AAV (p<0.001). The incidence rate of VTEs /100 person-year in patients with positive MPO-ANCA was 3.3 (95% CI 2-4.7) vs. 2.1 (95% CI 1.2-3.0) in patients with PR3-ANCA, p=0.1. Patients who developed any VTE were older at diagnosis and had higher BVAS score, were more likely to be MPO-ANCA positive and had higher VDI at 12 months after diagnosis of AAV (Table 1).

Conclusion:

Higher age at diagnosis of the vasculitis, MPO positivity and high disease activity were associated with VTEs. The incidence rate of AAV-related VTEs was higher early at disease onset compared to the whole period of follow-up.

Table 1. VTEs in 322 patients with ANCA Associated Vasculitis

All patients (n=322)

VTEs

(n=55)

No VTEs (n=267)

P-value

Age at diagnosis, mean ±SD, years.

64.4 ±16.4

68.8 ±13.9

63.5 ±16.8

0.03

Sex, Female, n (%)

150 (47)

23 (42)

127 (48)

0.4

Diagnosis: GPA: MPA: EGPA

166: 134: 22

26: 27: 2

140: 107: 20

PR3-ANCA +, n (%)

156 (51)

21 (41)

135 (54)

0.1

MPO-ANCA +, n (%)

138 (45)

32 (62)

106 (42)

0.01

BVAS at diagnosis, mean ±SD

15.3 ±6.2

17.1 ±7

14.6 ±6

0.009

Laboratory data at diagnosis

S-creatinine, μmol/l, median (IQR)

136 (74-308)

190 (76-355)

128 (73-283)

0.1

Haemoglobin, g/l mean ±SD

110 ±20

110 ±17

110 ±20

0.8

White blood cell count, mean ±SD

12 ±4.9

12 ±5.4

12 ±4.8

0.7

Platelet count mean ±SD

370 ±144

343 ±144

375 ±144

0.1

CRP, mg/l, median (IQR)

77 (23-134)

53 (11-121)

83 (26-143)

0.2

ESR, mm/hr, mean ±SD

64 ±33

62 ±30

64 ±34

0.8

eGFR ml/min/1.7m2, median (IQR)

44 (18-86)

30 (15-82)

47 (17-87)

0.3

Deaths, n (%)

144 (45)

28 (51)

116 (43)

0.3

ESRD, n (%)

51 (16)

9 (16)

42 (16)

0.9

BVAS at 12 months, mean ±SD

0.8 ±2.5

0.7 ±2.1

0.9 ±2.4

0.7

VDI, at 12 months, median (IQR)

1 (0-2)

2 (1-3)

1 (0-2)

0.1

GPA: granulomatosis with polyangiitis, MPA: microscopic polyangiitis, EGPA: eosinophil granulomatosis with polyangiitis, PR3: proteinase-3, MPO: myeloperoxidase, BVAS: Birmingham Vasculitis Activity Score, IQR: interquartile range, CRP: c-reactive protein, ESR: erythrocyte sedimentation rate eGFR: estimated glomerular filtration rate at disease onset, ESRD: end-stage renal disease, VDI: vasculitis damage index.


Disclosure: M. Liapi, None; D. Jayne, None; M. Segelmark, None; A. Mohammad, None.

To cite this abstract in AMA style:

Liapi M, Jayne D, Segelmark M, Mohammad A. Venous Thromboembolism in ANCA Associated Vasculitis. a Population-Based Cohort Study from Southern Sweden [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/venous-thromboembolism-in-anca-associated-vasculitis-a-population-based-cohort-study-from-southern-sweden/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/venous-thromboembolism-in-anca-associated-vasculitis-a-population-based-cohort-study-from-southern-sweden/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology